Stocks › CRSP
CRISPR Therapeutics AG
CRSP·Nasdaq·USD
$54.00
-3.34 (-5.82%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
CRSP
CRISPR Therapeutics AG · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CRSPS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of CRSP by members of U.S. Congress · 7 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Thomas R. SuozziHouse · D · NY |
CRSPCRISPR Therapeutics AG · Stock |
Sale $50,001 - $100,000 |
Oct 5, 2021 | Sep 20, 2021 | Filing ↗ |
| Thomas R. SuozziHouse · D · NY |
CRSPCRISPR Therapeutics AG · Stock |
Purchase $50,001 - $100,000 |
Sep 23, 2021 | Jun 3, 2021 | Filing ↗ |
 Marjorie Taylor GreeneHouse · R · GA |
CRSPCRISPR Therapeutics AG · Stock |
Purchase $1,001 - $15,000 |
Feb 19, 2021 | Jan 21, 2021 | Filing ↗ |
 James M InhofeSenate · R · OK |
CRSPCRISPR Therapeutics AG · Stock |
Sale $1,001 - $15,000 |
Jan 15, 2021 | Jan 5, 2021 | Filing ↗ |
| James M InhofeSenate · R · OK |
CRSPCRISPR Therapeutics AG · Stock |
Sale $50,001 - $100,000 |
Dec 23, 2020 | Dec 22, 2020 | Filing ↗ |
| James M InhofeSenate · R · OK |
CRSPCRISPR Therapeutics AG · Stock |
Sale $15,001 - $50,000 |
Jun 20, 2018 | Jun 19, 2018 | Filing ↗ |
| James M InhofeSenate · R · OK |
CRSPCRISPR Therapeutics AG · Stock |
Purchase $15,001 - $50,000 |
Nov 8, 2017 | Oct 19, 2017 | Filing ↗ |
Whale Activity
Position changes in CRSP reported for 2026-06-30 by 12 tracked institutional filers
- Increased5
- New1
- Held0
- Decreased1
- Closed0
- No prior filing5
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 8.3M | $455.4M | increased |
| TWO SIGMA INVESTMENTS, LP | 2.0M | $108.5M | increased |
| Amova Asset Management Americas, Inc. | 1.7M | $93.8M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $64.5M | increased |
| D. E. Shaw & Co., Inc. | 893.8K | $48.7M | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 648.7K | $35.4M | increased |
| CITADEL ADVISORS LLC | 465.8K | $25.4M | decreased |
| MILLENNIUM MANAGEMENT LLC | 382.0K | $20.8M | increased |
| Versant Venture Management, LLC | 148.8K | $8.1M | — |
| Palo Alto Investors LP | 39.6K | $2.2M | — |
| Abu Dhabi Investment Council Co P.J.S.C | 19.0K | $1.0M | — |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 2,000 | $109K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by CRSP insiders, by quarter · Form 4
Recent Insider Transactions
977 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| KASINGER JAMES R.General Counsel and Secretary | Sale | −10.4K | $60.24 | $626K | Sep 22, 2026 | Form 4 ↗ |
| Behbahani AliDirector · Director | Sale | −13.7K | $57.09 | $781K | Sep 17, 2026 | Form 4 ↗ |
| Patel NaimishChief Medical Officer | Sale | −3,786 | $55.62 | $211K | May 29, 2026 | Form 4 ↗ |
| Patel NaimishChief Medical Officer | Option exercise | +10.0K | — | — | May 28, 2026 | Form 4 ↗ |
| KASINGER JAMES R.General Counsel and Secretary | Sale | −3,182 | $46.78 | $149K | Mar 23, 2026 | Form 4 ↗ |
| Kulkarni SamarthChief Executive Officer · Director | Sale | −10.0K | $46.78 | $469K | Mar 23, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Sale | −3,708 | $46.78 | $173K | Mar 23, 2026 | Form 4 ↗ |
| KASINGER JAMES R.General Counsel and Secretary | Option exercise | +6,250 | — | — | Mar 20, 2026 | Form 4 ↗ |
| Kulkarni SamarthChief Executive Officer · Director | Option exercise | +19.7K | — | — | Mar 20, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Option exercise | +6,250 | — | — | Mar 20, 2026 | Form 4 ↗ |
| Patel NaimishChief Medical Officer | Sale | −3,150 | $48.26 | $152K | Mar 16, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Gift | −750 | $0.00 | $0 | Mar 16, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Sale | −4,021 | $48.26 | $194K | Mar 16, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Sale | −5,848 | $48.26 | $282K | Mar 16, 2026 | Form 4 ↗ |
| KASINGER JAMES R.General Counsel and Secretary | Sale | −3,450 | $48.26 | $166K | Mar 16, 2026 | Form 4 ↗ |
| Kulkarni SamarthChief Executive Officer · Director | Sale | −10.3K | $48.26 | $499K | Mar 16, 2026 | Form 4 ↗ |
| Patel NaimishChief Medical Officer | Option exercise | +8,125 | — | — | Mar 14, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Option exercise | +6,875 | — | — | Mar 14, 2026 | Form 4 ↗ |
| Prasad RajuChief Financial Officer | Option exercise | +10.0K | — | — | Mar 14, 2026 | Form 4 ↗ |
| KASINGER JAMES R.General Counsel and Secretary | Option exercise | +6,875 | — | — | Mar 14, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding CRSP · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $60.4M | 0.06% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 469.2K | $26.4M | 0.15% | May 31, 2026 |
| Avantis U.S. Small Cap Equity ETF American Century ETF Trust | 104.0K | $5.8M | 0.21% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund TIAA-CREF Funds | 121.6K | $5.8M | 0.14% | Jul 31, 2026 |
| Empower T. Rowe Price Mid Cap Growth Fund EMPOWER FUNDS, INC. | 93.4K | $5.1M | 0.25% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 VALUE INDEX FUND VANGUARD SCOTTSDALE FUNDS | 72.0K | $4.0M | 0.32% | May 31, 2026 |
| VANGUARD TOTAL WORLD STOCK INDEX FUND VANGUARD INTERNATIONAL EQUITY INDEX FUNDS | 75.4K | $3.6M | 0.00% | Jul 31, 2026 |
| Direxion Daily S&P Biotech Bull 3X Shares Direxion Shares ETF Trust | 68.3K | $3.3M | 0.66% | Jul 31, 2026 |
| Nuveen Equity Index Fund TIAA-CREF Funds | 67.2K | $3.2M | 0.01% | Jul 31, 2026 |
| iShares Genomics Immunology and Healthcare ETF iShares Trust | 62.2K | $3.0M | 1.57% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list CRSP's shares (CUSIP H17182108), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Allan Gray Australia Pty LtdSCHEDULE 13G/A · passive (13G) · 15.8K shares0.0%
Aug 14, 2026 · ↗ - ORBIS INVESTMENT MANAGEMENT LTDSCHEDULE 13G/A · passive (13G) · 5.4M shares5.6%
Aug 14, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 8.0M shares8.3%
Jul 27, 2026 · ↗ - Allan Gray Australia Pty LtdSCHEDULE 13G/A · passive (13G) · 15.8K shares0.0%
May 15, 2026 · ↗ - ORBIS INVESTMENT MANAGEMENT LTDSCHEDULE 13G/A · passive (13G) · 6.1M shares6.3%
May 15, 2026 · ↗ - Capital World InvestorsSCHEDULE 13G · passive (13G) · 4.9M shares5.1%
May 14, 2026 · ↗ - Catherine D. WoodSCHEDULE 13G/A · passive (13G) · 11.3M shares11.8%
Apr 30, 2026 · ↗ - ARK Investment Management LLCSCHEDULE 13G/A · passive (13G) · 11.3M shares11.8%
Apr 30, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming crispr therapeutics ag as client
No lobbying filings found naming CRISPR Therapeutics AG as the client.
Government Contracts
Federal awards to CRISPR Therapeutics AG · USAspending
No federal contract awards found for CRISPR Therapeutics AG.
U.S. Patents
Recent USPTO applications naming CRISPR Therapeutics AG
No USPTO patent applications found for CRISPR Therapeutics AG.
Annual Financials
From CRSP's 10-K filings · XBRL
No annual XBRL figures on record for CRSP. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in CRSP's price history.
About CRISPR Therapeutics AG
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersZUG
IncorporatedV8
SEC CIK0001674416 ↗
Former namesCRISPR Therapeutics AG